Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

Zhejiang Provincial People's Hospital

Status and phase: Enrolling; Phase 3

Conditions: Abatacept; Treatment Compliance; Rheumatoid Arthritis

Treatments: Drug: Abatacept; Drug: Janus Kinase Inhibitor

Study type: Interventional

Funder types: Other

Identifiers

NCT05451615

KY2022018

Details and patient eligibility

About

The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients

Enrollment: 90 estimated patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Meet the above diagnostic criteria for refractory rheumatoid arthritis
2. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological/targeted disease-improving anti-rheumatic drugs is ineffective, and abatacept combined with a JAK inhibitor is required treated patients

Exclusion criteria

1. Patients with tumors, hematological diseases, and other autoimmune diseases
2. Those who have a history of allergies to the drugs selected in this study
3. Those who cannot adhere to abatacept combined with JAK inhibitor therapy, or who have serious adverse reactions and did not complete the observation period prescribed by the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

90 participants in 2 patient groups

Abatacept

Experimental group

Description:

D2T RA patients receive Abatacept

Treatment:

Drug: Abatacept

JAK inhibitor

Experimental group

Description:

D2T RA patients receive JAKi

Treatment:

Drug: Janus Kinase Inhibitor

Drug: Abatacept